ERBB2 and breast carcinoma: These subregions are hypothesized to reflect underlying biological differences and have been used to predict several cancer‐relevant biomarkers, including EGFR mutation and nodal status in lung cancer [26, 32], HER2 status in breast cancer [33], and Ki‐67 expression in laryngeal cancer [34].